Recombinant FOLR1 (Mirvetuximab Biosimilar) anticorps
Aperçu rapide pour Recombinant FOLR1 (Mirvetuximab Biosimilar) anticorps (ABIN7581416)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
-
-
Expression System
- CHO Cells
-
Fonction
- Anti-FOLR1 / FRA Reference Antibody (mirvetuximab)
-
Séquence
- QVQLVQSGAE VVKPGASVKI SCKASGYTFT GYFMNWVKQS PGQSLEWIGR IHPYDGDTFY NQKFQGKATL TVDKSSNTAH MELLSLTSED FAVYYCTRYD GSRAMDYWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG,DIVLTQSPLS LAVSLGQPAI ISCKASQSVS FAGTSLMHWY HQKPGQQPRL LIYRASNLEA GVPDRFSGSG SKTDFTLTIS PVEAEDAATY YCQQSREYPY TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
-
Attributs du produit
- Anti-FOLR1 Reference Antibody (mirvetuximab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.2 kDa.
-
Pureté
- >95 %
-
Isotype
- IgG1
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Commentaires
-
Therapeutic Agents by Target and Mechanism: FOLR1 antagonist
Conditions: Ovarian Cancer
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Stock
- 4 °C,-80 °C
-
Stockage commentaire
- +4°C,-80°C
-
-
- FOLR1 (Mirvetuximab Biosimilar)
-
Classe de substances
- Biosimilar
-
Sujet
- Synonyms: FOLR1, Folate receptor 1
-
Poids moléculaire
- 145.2 kDa
-
UniProt
- P15328
Antigène
-